Key result
High-concentration aspirin inhibits cultured vascular smooth muscle cell proliferation by up to ~90%.
ASA inhibits human smooth muscle cell proliferation in vitro; leaves open clinical relevance for vascular disease.
The growth of human smooth muscle cells in culture is inhibited by acetylsalicylic acid (ASA). In comparison to control, the proliferation of cells treated with 270 mg/L lysinmono(acetylsalicylate)/30 mg/L glycine was inhibited by 50-90% under different culture conditions. Cell numbers per well (control vs. treated) were as follows: (a) 470,500 +/- 55,890 vs. 24,750 +/- 4,030 (p < 0.002) after 6 days in the presence of 10% fetal calf serum (FCS), (b) 160,500 +/- 9,920 vs. 74,000 (p < 0.001) after 8 days in the presence of 10% human serum; and (c) 387,000 +/- 29,420 vs. 35,250 +/- 1,110 (p < 0.001) after 8 days in the presence of 5% FCS. Significant inhibition of growth by lysinmono(acetylsalicylate) at 90 mg/L was noted only for cultures grown with 10% FCS. Lower concentrations of this drug were ineffective under all culture conditions. Higher dosages of ASA, which would prevent not only platelet aggregation but also smooth muscle cell growth, may therefore be indicated in therapy of patients who undergo percutaneous transluminal coronary angioplasty (PTCA) or coronary artery transplantation.
No takes yet. Share an insight, caveat, or question.
Bernhardt et al. (1993) studied Vascular smooth muscle cell proliferation. Acetylsalicylic acid (lysinmono(acetylsalicylate)/glycine) vs. Control culture was evaluated on Vascular smooth muscle cell proliferation (cell numbers per well) (p=<0.002). High-concentration acetylsalicylic acid (270 mg/L) inhibited cultured human vascular smooth muscle cell proliferation by 50-90% compared to control (P<0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: